CTOs on the Move

Frontier Medicines

www.frontiermeds.com

 
Frontier Medicines is a pre-clinical stage biopharmaceutical company developing breakthrough medicines that redefine the course of debilitating diseases. According to the American Cancer Society, 1,762,000 new cancer cases and 607,000 deaths from cancer are expected to occur in the US in 2019. Our focus is developing treatments against important cancer-causing proteins that the biopharma industry hasn`t found a way to treat (or “drug”) with pharmaceutical interventions. After decades of research, this has become one of the most critical challenges in addressing human disease and advancing oncology therapy --central to the research at Frontier Medicines. Frontier Medicines is using chemoproteomics – ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.frontiermeds.com
  • 151 Oyster Point Boulevard 2nd Floor
    South San Francisco, CA USA 94080
  • Phone: 650.457.1005

Executives

Name Title Contact Details
James Winkler
Head of Degrader Technology Profile
Johannes Hermann
Chief Technology Officer Profile

Funding

Frontier Medicines raised $M67 on 06/25/2019

Similar Companies

Lumos Diagnostics

Lumos Diagnostics delivers custom diagnostic solutions by combining deep market insight with existing platform technologies, assay development capability and regulated manufacturing experience.

Genfit

GENFIT is a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases where there are considerable unmet medical needs, corresponding to a lack of approved treatments. GENFIT is a leader in the field of nuclear receptor-based drug discovery with a rich history and strong scientific heritage spanning almost two decades. Its most advanced drug candidate, elafibranor, is currently evaluated in pivotal Phase 3 clinical trial (“RESOLVE-IT”) as a potential treatment for nonalcoholic steatohepatitis, or NASH. NASH is considered by regulatory authorities as a medical emergency because of its potentially severe consequences, although often asymptomatic until late stages, and because its prevalence is on the rise. Elafibranor has also obtained positive preliminary results in a Phase 2 clinical trial in primary biliary cholangitis (PBC), a severe chronic liver disease. As part of GENFIT’s comprehensive approach to clinical management of NASH patients, the Company is also developing a new, non-invasive and easy-to-access blood-based in vitro diagnostic, or IVD, test to identify patients with NASH who may be appropriate candidates for drug therapy. With facilities in Lille and Paris, France, and Cambridge, MA, USA, the Company has approximately 170 employees. GENFIT is a public company listed on the Nasdaq Global Select Market and in compartment B of Euronext’s regulated market in Paris.

iChip

LifeNexus is the creator of iChip, a product that empowers consumers with their health information anywhere they need it. By working with health plans, employers and providers, we`re helping to create better healthcare experiences when it matters most.

LIGNO TECH USA

LIGNO TECH USA is a Bridgewater, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cell Biosciences Inc

Cell Biosciences Inc is a Santa Clara, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.